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Objective: We examined relationships between inpatient medical treatment, reperfusion
therapy and in-hospital mortality among patients with ST-elevation myocardial infarction
(STEMI) in Russia.
Methods: Clinical information about 25,682 patients with STEMI enrolled in the 2010–2011
registry was included retrospectively  in the study. Performance of the key guideline-recom-
mended treatment interventions was assessed. Timeliness of reperfusion therapy was evalu-
ated with the help of the following ACC/AHA clinical measures (2008): Time to ﬁbrinolytic
therapy, Time to primary percutaneous coronary intervention (PCI) and Reperfusion therapy.
Multivariate logistic and Cox's regression models were used to assess the relationship between
different in-hospital treatment interventions and the risk of in-hospital death among patients
with STEMI under the control of patient characteristics and comorbidities.
Results: The average age of patients was 63 (55–74) years. 34% of patients were female.
Survived patients differed signiﬁcantly from deceased ones in the majority of demographic,
anamnesis, clinical presentation and treatment parameters. Hospital treatment with ACE-Is
or ARBs, b-blockers and statins was signiﬁcantly associated (x2 = 482.1, P < 0.0001) with
lower inpatient mortality. Prognostic value of reperfusion therapy and measures of its
timeliness were not statistically signiﬁcant (P  0.05 for Wald test for each factor).
Conclusion: STEMI treatment with ACE-Is or ARBs, b-blockers and statins during hospital
stay (not necessarily at arrival) inﬂuences upon the rate of death in hospital as strong as the
patient clinical status at admission. Reperfusion and its performance are additional factors
that inﬂuence indirectly on the risk of in-hospital mortality in patients with STEMI.
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Introduction (iii)
patient's hospital chart is ﬁnished;
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syndrome (ACS) is an important problem of contemporary
cardiology. Many studies are devoted to this problem [1–4, etc.].
Different algorithms have been proposed for estimating the risk
of death after ACS (GRACE, TIMI) [5,6]. In the most known
algorithms, all factors determining the probability of death in
patients with ACS are patient-related, e.g. age, sex, history of
cardiovascular diseases (CVD), family history of coronary artery
disease (CAD) and premature death, and clinical status at
admission. To optimize treatment it is important to study the
impact of treatment-related factors (hospital drug treatment
and timeliness of reperfusion) on the patient risk.
Recently, much attention is paid to the study of risk factors in
patients with ST-elevation myocardial infarction (STEMI)
treated with primary percutaneous coronary intervention
(PCI) [7,8, etc.]. It is well known that the quality of reperfusion
therapy is a risk factor of a short-term mortality in patients with
STEMI patients [9,10]. The American College of Cardiology and
the American Heart Association have published in 2008 the task
force on performance measures for STEMI and non-STEMI [11].
Clinical measures (Time to ﬁbrinolytic therapy, Time to PCI and
Reperfusion therapy) have been designed to assess the quality
of primary reperfusion therapy in patients with STEMI.
In the present retrospective study we examined relation-
ships between different patient-related factors (patient's
clinical characteristics), treatment-related factors (hospital
drug treatment and reperfusion therapy and its performance)
and in-hospital mortality among Russian patients with STEMI.
Materials and methods
Data source
The Registry of Acute Coronary Syndrome of the Ministry of
Health of Russian Federation (hereafter referred as Russian
ACS Registry) was used as a source of data about ACS patients
[12]. It is a retrospective, continuous, nation-wide, Web-based
registry operating on-line. Participation in the Russian ACS
Registry is voluntary. The access to the registry is given only to
registered members.
The Registry database was developed using ACCF/AHA 2011
Key Data Elements and Deﬁnitions of a Base Cardiovascular
Vocabulary for Electronic Health Records [13]. Data on clinical
characteristics, prior, hospital drug treatment and reperfusion
therapy was collected. Data on post-hospital treatment of ACS
patients was not included in the Russian ACS Registry
database. The source of patient's data was a hospital chart.
Centers participating in the Russian ACS Registry are asked
to include continuously all patients following inclusion/
exclusion criteria who were treated from ACS during the year
prior to the year of participation.
Russian ACS Registry inclusion criteria [14] are the
following:
(i) age 18 years;
(ii) any type of ACS as a presumptive diagnosis;(iv) absence of any exclusion criteria.
Russian ACS Registry exclusion criteria [14] are the
following:
(i) symptoms considered as consistent with acute cardiac
ischemia are absent within the last 24 h prior to
admission;
(ii) patient was transferred into a registry hospital in more
than 24 h after admission to the initial hospital;
(iii) patient was transferred out of a registry hospital in less
than 24 h after admission;
(iv) ACS symptoms occurred after hospitalization at other
reasons;
(v) ACS is accompanied by a signiﬁcant co-morbidity such as a
motor vehicle accident, trauma, severe gastrointestinal
bleeding, operation or procedure directly before admission.
Patient selection
Retrospective data on clinical characteristics, prior and hospital
drug treatment, reperfusion therapy and in-hospital mortality
contained in the 2010–2011 Russian ACS Registry from 25,682
patients with STEMI were examined. The average age of
patients was 63 (55–74) years. 34% of patients were female.
These patients were treated in 155 cardiological units located in
46 regions of Russia. Death was deﬁned as endpoint of study.
Duration of hospital treatment was from 9 to 21 days for
survived patients. Mortality rate was 8.1%. Most deﬁnitions of
clinical data in the Russian ACS Registry are consistent with
W.S. Weintraub et al. [13].
We used the following criteria to select patients for the
study:
(i) diagnosis of STEMI (data from the Russian ACS Registry)
(ii) age between 18 and 80 years.
The patients were excluded from the study if they had
missing data on the time of reperfusion (time of ﬁbrinolytic
agent injection and/or time of balloon inﬂation during PCI),
hospital presentation and treatment.
The patients over 80 years were not included in the present
study because of proven disparities in treatment of ACS in the
elderly and younger subjects [15–17]. It was previously
reported that high age itself is a predominant clinical factor
inﬂuencing on implementation of recommended (especially
invasive) treatment among aged patients in Russia in spite of
their higher risk of in-hospital death [18,19]. This limitation of
the present study is indicated in the Limitation section.
Patient-related and treatment-related factors in patients with
STEMI
All clinical factors, which could not be changed by medical care
of present event, were named as patient-related factors. Other
factors, which could be modiﬁed by treatment, were named as
treatment-related factors.
Patient-related factors included age, sex, body mass index
(BMI), smoking, prior myocardial infarction (MI), history of
Fig. 1 – Survival plot for patients with STEMI.
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heart disease (PHD), history of chronic heart failure (CHF), prior
stroke, history of peripheral vascular disease (PVD), history of
chronic renal insufﬁciency (CRI), history of chronic lung
disease (CLD), history of arterial hypertension (AH), diabetes,
acute heart failure (AHF) Killip 1–4 at admission, heart rate
(HR), systolic blood pressure (SBP), diastolic blood pressure
(DBP), pathologic Q wave on electrocardiogram (ECG), right
ventricle (RV) dilatation, acute left ventricle (LV) aneurism,
thrombus into LV, prior treatment with aspirin, clopidogrel,
nitrates, angiotensine converting enzyme inhibitors (ACE-Is)
or angiotensin receptors blockers (ARBs), beta-blockers,
dihydropyridine calcium antagonists (DCA), non-dihydropyr-
idine calcium antagonists (NDCA) and statins.
Treatment-related factors included hospital treatment
with aspirin, clopidogrel, nitrates, heparin, fondaparinux,
ACE-Is or ARBs, beta-blockers, DCA, NDCA, statins, the fact
of any reperfusion and timeliness of reperfusion.
One of the factors considered in the analysis was LV
ejection fraction (LVEF). LVEF was regarded as combined
patient- and treatment-related factor. In Russian STEMI
patients LVEF is measured later during the hospital stay.
Thus, contractile dysfunction due to infracted myocardium
(patient-related component) is compensated by myocardium
salvage and recovery of function due to timely treatment
(treatment-related component).
Deﬁnitions for all clinical factors are shown in Table 1.
Performance measures for reperfusion
Reperfusion therapy was estimated basing on the following
performance measures powered by American College of
Cardiology and American Heart Association (ACC/AHA) in
2008 year [11]:
(i) No. 7 – Time to ﬁbrinolytic therapy, which determines the
part of patients with STEMI whose time from hospital
admission to ﬁbrinolytic therapy is 30 min or less,
(ii) No. 8 – Time to PCI, which determines the part of patients
with STEMI whose time from hospital admission to
primary PCI is 90 min or less,
(iii) No. 9 – Reperfusion therapy, which determines the part of
patients with STEMI who receive any reperfusion treat-
ment within 12 h of symptom onset.
ACC/AHA performance measures were estimated in those
STEMI patients who met the measure inclusion and exclusion
criteria [11].
Statistical analysis
We applied the Shapiro–Wilk test to check whether the data
were approximately normally distributed. Since some data
occurred to be non-normal, their further analysis was carried
out using non-parametric statistical methods. We applied the
Chi-square (x2) test to compare the binary variables and to
compute the signiﬁcance level for the difference between two
proportions. Mann–Whitney test was used to compare the
continuous variables. Categorical data are presented as
frequencies and percentages. Continuous variables arereported as mean, medians (Me) with standard deviations
(SD) and inter-quartile ranges (Q1, Q3).
Cox's proportional hazard models were used for multivari-
ate analysis of dependence between fatal cardiovascular event
(death) and various factors (patient-related and treatment-
related) during inpatient admission (in hours). We selected the
factors for multivariate analysis basing on the results of
univariate comparison between deceased patients and sur-
vived patients (P < 0.05 in Table 2).
In our study the risk index Exp(B) estimates the hazard ratio
of in-hospital mortality. The risk index Exp(B) is the ratio of
hazards between two individuals whose values of x1 differ by
one unit while all other covariates are held constant. In Cox
regression the hazard function is modeled as h(t) = h0(t)exp
(b0x), where h0(t) is the baseline hazard, which cannot be
estimated. In spite of this, one can estimate b. If b = 0, then the
hazard ratio for this covariate is equal to Exp0 = 1, i.e., this
covariate does not affect survival.
The obtained estimations were considered statistically
signiﬁcant if P < 0.05. For the statistical analysis, the software
package Statistica 6.1 (Statsoft Inc., USA) was used.
Results
Characteristics of the registry population with STEMI
Clinical characteristics of enrolled patients with STEMI are
presented in Table 2. Total rate of death in hospital was 8.1%.
Survival plot is shown in Fig. 1. Clinical characteristics of
deceased patients and survive patients are shown separately.
The average age of enrolled patients was 63 (55–74) years.
34% of patients were female. 29.9% of patients admitted to
hospital with acute heart failure and 36.6% of patients
admitted with pathological Q-wave on electrocardiogram.
More than half of all patients with STEMI had the left ventricle
systolic dysfunction (ejection fraction is less than 49%).
Survived patients differed signiﬁcantly from deceased patients
in the majority of demographics, anamnesis, clinical presen-
tation and treatment parameters (Table 2).
Table 1 – Definitions of clinical factors used in the present study.
Factor name Deﬁnition Value domain
Sex – Male
Female
Age Age at admission. Age can be from 18 to 80, according to the following criteria. Numeric, years
BMI BMI = height/(weight)2 Numeric, kg/m2
Weight is a measured actual weight in kilograms.
Height is a measured actual height in meters.
Prior MI Documented history of MI Yes
No
History of stable angina pectoris Documented history of stable angina pectoris Yes
No
Family history of PHD Indicate if the patient has/had any direct blood relatives (i.e., parents, siblings,
children) who have had any of the following diagnosis at age <55 years for male
relatives or <65 years for female relatives: coronary artery disease (i.e., angina,
previous CABG or PCI), MI, sudden cardiac death without obvious cause.
Yes
If the patient is adopted or the family history is unavailable, code ‘‘No’’. No
Prior PCI Documented prior PCI Yes
No
History of CHF Documented history of CHF Yes
No
Prior stroke Documented history of stroke, including temporary stroke Yes
No
History of PVD Current or previous history of PVD (lower extremity from iliac to tibials and
upper extremity from subclavian to brachials. Renal, coronary, cerebral, and
mesenteric vessels and aneurysms are excluded).
Yes
No
History of CRI Documented history of CRI Yes
No
History of CLD Documented history of CLD (e.g., CODL, chronic bronchitis) or currently receiving
long-term treatment with inhaled or oral pharmacological therapy (e.g., beta-
adrenergic agonist, anti-inﬂammatory agent, leukotriene receptor antagonist, or
steroid) for the indication of lung disease.
Yes
No
History of AH Current or previous diagnosis of hypertension Yes
No
Smoking Current or previous use of any tobacco product, including cigarettes, cigars,
pipes, and chewing tobacco, captured as smoking status.
Yes
No
History of diabetes History of diabetes diagnosed and/or treated by a physician. Yes
No
Prior drug treatment Treatment with selected drugs prior to the current STEMI Yes
- Aspirin No (for each drugs)
- Clopidogrel
- Nitrates
- ACE-Is or ARBs
- b-blockers
- DCA
- NDCA
- Varfarin
- Statins
Clinical status of patients at admission to hospital
HR Number of heartbeats over 1 min Numeric, bpm
HR > 100 bpm Yes
No
SBP SBP in millimeters mercury Numeric, mmHg
SBP > 140 mmHg Yes
No
DBP DBP in millimeters mercury Numeric, mmHg
DBP > 90 mmHg Yes
No
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Table 1 (Continued )
Factor name Deﬁnition Value domain
AHF AHF at admission Killip 1
Killip 2
Killip 3
Killip 4
Pathological Q-wave on ECG New pathological Q-wave on ECG Yes
No
LVEF The calculated resting LVEF as either a percentage value or the midpoint
value when a range is reported.
Numeric, %
LVEF < 50% Yes
No
LVEF < 35% Yes
No
RV dilatation RV dilatation diagnosed by echocardiography Yes
No
Acute LV aneurism New LV aneurism diagnosed by echocardiography. Yes
If prior data of echocardiography is unavailable, code ‘‘No’’. No
Thrombus into LV Thrombus into LV diagnosed by echocardiography. Yes
No
Total cholesterol Blood total cholesterol Numeric, mmol/L
Triglycerides Blood triglycerides Numeric, mmol/L
Creatinine Blood creatinine Numeric, micromoles/L
Blood glucose Fasting blood glucose Numeric, mmol/L
Hospital treatment
PCI Performed PCI Yes
No
CABG Performed CABG Yes
No
Fibrinolytic therapy Performed ﬁbrinolytic therapy Yes
No
Drug treatment, %: Hospital drug treatment Yes
- Aspirin No (for each drugs)
- Clopidogrel
- Nitrates
- Anticoagulants
- ACE inhibitors or ARBs
- b-blockers
- DCA
- NDCA
- Varfarin
- Statins
CODL, chronic obstructive disease of lungs; CABG, coronary artery bypass grafting.
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the ﬁrst day and 2.3% later than 24 h after admission). 29.3% of
all STEMI patients received ﬁbrinolisys and 0.4% of patients
received coronary artery bypass graft (CABG) during the ﬁrst
24 h after admission.
Selection of patients for carrying out ACC/AHA measures
showed the following results. ACC/AHA measure ‘‘Time to
ﬁbrinolisys’’ could be estimated for 5119 STEMI patients (19.9%
of general group of 25,682 patients). ACC/AHA measure ‘‘Time
to PCI’’ could be estimated for 3993 STEMI patients (15.5% of
general group of 25,682 patients). ACC/AHA measure ‘‘Reper-
fusion therapy’’ could be estimated for 12,043 patients with
STEMI (46.9% of general group of 25,682 patients).Assessment of the quality of reperfusion with the help of
ACC/AHA measures (see the section Performance measures
for reperfusion) showed the following results. In 65.3% of
applicable STEMI patients (3343 from 5119 patients) the time
from hospital arrival to ﬁbrinolytic therapy was 30 min or less
(ACC/AHA measure No.7 ‘‘Time to ﬁbrinolisys’’). In 70.0% of
applicable STEMI patients (2795 from 3993 patients) the time
from hospital arrival to primary PCI was 90 min or less (ACC/
AHA measure No. 8 ‘‘Time to PCI’’). 81.4% of applicable STEMI
patients (9803 from 12,043 patients) received ﬁbrinolytic
therapy or primary PCI (ACC/AHA measure No. 9 ‘‘Reperfusion
therapy’’). It is important that obtained results of ACC/AHA
measures were derived from the data of applicable STEMI
Table 2 – Baseline characteristics of 25,682 patients with STEMI.
Parameter All patients
(n = 25682)
Deceased patients
(n = 2080)
Survived patients
(n = 23602)
P-level
Male sex, % 66.0 47.4 67.6 <0.001
Age, years, Me (Q1, Q3) 63 (55, 74) 74 (64, 80) 62 (54, 72) <0.001
Height, m, Me (Q1, Q3) 1.67 (1.55, 1.74) 1.60 (1.55, 1.69) 1.67 (1.56, 1.74) <0.001
Weight, kg, Me (Q1, Q3) 75 (58, 85) 68 (59, 80) 75 (60, 85) <0.001
BMI, kg/m2, Me (Q1, Q3) 27.2 (24.7, 30.4) 27.3 (24.6, 30.8) 27.2 (24.8, 30.4) 0.774
Prior MI, % 21.6 25.0 21.3 <0.001
History of Stable angina pectoris, % 46.1 50.0 45.6 0.001
Family history of PHD, % 32.0 24.0 33.6 <0.001
Prior PCI, % 2.2 0.9 2.3 <0.001
Prior CABG, % 0.03 0 0.03 0.430
History of CHF, % 36.4 43.2 35.8 <0.001
Prior stroke (including temporary stroke), % 8.1 13.1 7.7 <0.001
History of PVD, % 5.2 6.1 5.1 0.049
History of CRI, % 2.7 5.3 2.5 <0.001
History of CLD, % 8.8 9.7 8.7 0.122
History of AH, % 84.0 88.4 83.6 <0.001
Smoking, % 33.0 16.0 34.5 <0.001
History of Diabetes 1 type, % 0.7 1.4 0.6 <0.001
History of Diabetes 2 type, % 14.5 19.4 14.1 <0.001
Prior drug treatment, %
- Aspirin 26.8 25.9 28.1 0.679
- Clopidogrel 3.4 2.2 3.5 0.002
- Nitrates 24.3 28.4 23.9 <0.001
- ACE-Is or ARBs 38.0 39.7 37.8 0.087
- b-blockers 25.4 23.1 25.6 0.012
- DCA 5.3 4.8 5.3 0.327
- NDCA 1.5 1.6 1.5 0.720
- Varfarin 0.8 0.9 0.8 0.625
- Statins 9.5 6.6 9.8 <0.001
Clinical status of patients at admission to hospital
HR, bpm, median (Q1, Q3) 78 (68, 88) 84 (70, 100) 78 (68, 88) <0.001
SBP, mmHg, median (Q1, Q3) 135 (120, 150) 120 (90, 140) 140 (120, 150) <0.001
DBP, mmHg, median (Q1, Q3) 80 (70, 90) 70 (60, 90) 80 (75, 90) <0.001
AHF, %
- Killip 1 70.1 42.2 70.8
- Killip 2 22.3 36.3 21.9
- Killip 3 4.7 9.6 4.6
- Killip 4 2.9 11.9 2.7
Pathological Q-wave on ECG, % 36.6 41.9 36.1 <0.001
LVEF, %, median (Q1, Q3) 49 (38, 57) 21 (12, 32) 50 (41, 58) <0.001
RV dilatation, % 7.3 21.3 6.1 <0.001
Acute LV aneurism, % 8.5 19.7 7.5 <0.001
Thrombus into LV, % 4.2 7.1 3.9 <0.001
Total cholesterol, mmol/L, median (Q1, Q3) 4.8 (3.5, 5.8) 4.6 (3.1, 5.0) 4.9 (3.8, 5.9) <0.001
Triglycerides, mmol/L, median (Q1, Q3) 0.9 (0.2, 1.6) 0.76 (0.3, 0.98) 1.0 (0.2, 1.7) <0.001
Creatinine, micromoles/L, median (Q1, Q3) 87 (60, 107) 91 (62, 132) 87 (65, 106) 0.065
Blood glucose, mmol/L, median (Q1, Q3) 5.5 (4.4, 7.2) 6.5 (2.7, 9.8) 5.5 (4.5, 7.1) <0.001
Hospital treatment
PCI at the 1st day, % 18.5 7.9 19.6 <0.001
PCI after the 1st day, % 2.3 0.9 2.3 <0.001
CABG at the 1st day, % 0.02 0 0.02 0.519
CABG after the 1st day, % 0.4 0.5 0.4 0.829
Fibrinolytic therapy, % 29.3 24.5 29.7 <0.001
Drug treatment, %
- Aspirin 96.9 90.2 97.5 <0.001
- Clopidogrel 81.3 66.6 82.6 <0.001
- Nitrates 86.1 72.9 87.3 <0.001
- Anticoagulants 96.0 96.6 95.9 0.120
- ACE inhibitors or ARBs 82.4 44.6 85.7 <0.001
- b-blockers 89.4 56.0 92.3 <0.001
- DCA 9.7 2.1 10.4 <0.001
- NDCA 1.9 1.0 2.0 0.001
- Varfarin 2.7 1.0 2.8 <0.001
- Statins 78.2 46.4 81.0 <0.001
Hospital stay length, hours, median (Q1, Q3) 377 (293, 457) 34 (5, 117) 385 (315, 465) <0.001
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AHA measures differed signiﬁcantly on conversion to the
general group of patients. ACC/AHA measure No. 7 ‘‘Time to
ﬁbrinolisys’’ was fulﬁlled in 13.0% of all STEMI patients
enrolled in the study (3343 from 25,682 patients). 10.9% (2795
from 25,682 patients) and 38.2% (9803 from 25,682 patients) of
all studied STEMI patients met ACC/AHA measure No. 8 ‘‘Time
to PCI’’ and ACC/AHA measure No. 9 ‘‘Reperfusion therapy’’,
respectively.
Effect of treatment- and patient-related factors on survival in
patients with STEMI
We evaluated a relationship between all patient- and
treatment-related factors and the risk of in-hospital mortality
from any cardiovascular event in the general group of patients
with STEMI using multivariable Cox's regression model. This
model gives x2 = 482.1 (P < 0.0001). The values of the main
clinical characteristics in the model are summarized in Table 3.
Statistically signiﬁcant parameters have P-level less than 0.05
(these 15 factors are marked with bold type in Table 3).
The regression coefﬁcient b for these factors indicates that
the risk of in-hospital mortality in patients with STEMI
increases with the increase of age, heart rate, acute heart
failure Killip, blood glucose and right ventricular dilatation
and with the presence of pathological Q-wave on ECG and
acute left ventricular aneurism. The risk increases with the
decrease of left ventricular ejection fraction, diastolic bloodTable 3 – Clinical characteristics in the Cox's regression model 
with STEMI.
Parameter Regression
coefﬁcient b
Stan
er
LVEF S0.035 0.0
ACE-Is or ARBs (H.tr.) S0.854 0.1
Age 0.026 0.0
HR 0.009 0.0
DBP S0.012 0.0
AHF Killip 1–4 0.240 0.0
b-blockers (H.tr.) S0.608 0.1
Statins (H.tr.) S0.531 0.1
Path. Q-wave on ECG 0.448 0.1
Blood glucose 0.007 0.0
RV dilatation 0.456 0.1
Male sex S0.344 0.1
Acute LV aneurism 0.407 0.1
Triglycerides S0.161 0.0
Aspirin (H.tr.) 0.564 0.3
Prior stroke (including temporary stroke) 0.257 0.2
Total cholesterol 0.038 0.0
Clopidogrel (H.tr.) 0.206 0.1
SBP 0.005 0.0
Family history of PHD 0.133 0.1
Thrombus into LV 0.250 0.3
b-blockers (Pr.tr.) 0.133 0.1
Prior MI 0.117 0.1
Nitrates (H.tr.) 0.118 0.1
Prior PCI 0.384 0.7
etc.
Path., pathological; Pr.tr., prior treatment; H.tr., hospital treatment; measpressure and triglycerides and with the lack of hospital
treatment by angiotensin-converting enzyme inhibitors
(ACE-Is), angiotensin-receptor blockers (ARBs), b-blockers
and statins.
Prognostic value of other clinical factors, including any
reperfusion therapy and measures of its timeliness, exploited
the assessment of risk of in-hospital mortality using Cox's
regression models was not statistically signiﬁcant (P  0.05 for
Wald test for each factor), Table 3.
Since short duration of stay in hospital may hamper
performance of recommended treatment interventions and
consequently distort the extent of their inﬂuence on in-
hospital mortality, we compared clinical characteristics and
treatment of STEMI patients who have died during the ﬁrst
24 h after admission (n = 125; 6.0% of all deceased pts.) and
later on (n = 1955; 94.0% of all deceased pts.). Statistically
signiﬁcant difference between the selected subgroups was
observed just in administration of ACE-Is/ARBs (30.4% vs
45.5%, respectively, P = 0.024). The subgroups were compara-
ble with respect to other clinical and treatment parameters. In
patients who have died during the ﬁrst 24 h after admission,
ACE-Is or ARBs were administered rarely in comparison with
the patients who have deceased later. But it was not
associated with the severity of their clinical status. Thus,
the degree of ACE-Is and ARBs inﬂuence on the ﬁrst-day
mortality needs further research. As for in-hospital mortality
in general, the Cox's regression model used for the analysis
took into account the time (in hours) from hospital admissionfor evaluation of the risk of in-hospital mortality in patients
dard
ror
Risk
index Exp(B)
Wald
test
Statistical
signiﬁcance level P
05 0.965 52.26 <0.001
54 0.426 30.93 <0.001
06 1.026 18.00 <0.001
02 1.009 13.09 <0.001
07 0.977 13.01 <0.001
66 1.271 12.97 <0.001
75 0.544 12.12 <0.001
53 0.588 12.09 <0.001
35 1.565 11.07 <0.001
03 1.007 7.78 0.005
71 1.578 7.13 0.008
46 0.709 5.51 0.019
80 1.503 5.11 0.024
79 0.851 4.08 0.043
02 0.569 3.48 0.062
04 1.293 1.59 0.207
30 0.963 1.55 0.212
75 1.228 1.37 0.240
04 0.995 1.22 0.269
57 0.875 0.71 0.397
09 0.779 0.65 0.419
93 0.875 0.47 0.489
77 0.889 0.43 0.508
96 1.125 0.36 0.548
24 0.681 0.28 0.596
., measure.
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factors on patient.
Discussion
In our study we examined the impact of guideline-recom-
mended inpatient interventions on in-hospital mortality of
patients with STEMI using the data of Russian Acute Coronary
Syndrome Registry. It is shown that
(1) the lack of in-hospital treatment with ACE-Is, ARBs, b-
blockers and statins is the major treatment-related factor
related signiﬁcantly with the increased risk of death in
hospital;
(2) the performance of reperfusion therapy is not the leading
factor inﬂuencing on in-hospital mortality;
(3) the present-day completeness of data obtained retrospec-
tively from patients' medical records is deﬁcient for
estimating ACC/AHA measures of reperfusion quality
(ACC/AHA measures ‘‘Time to ﬁbrinolisys’’, ‘‘Time to PCI’’
and ‘‘Reperfusion therapy’’ were estimated for 19.9%, 15.5%
and 46.9% of patients, respectively, from general group).
The obtained results allowed us to reveal the most
important treatment interventions. The showed the care gaps
and gave the opportunities to upgrade the national STEMI
performance measurement set.
We have found only one similar study in literature, which
investigate relationship between hospital process perfor-
mance and outcomes in patients with non-ST elevation acute
coronary syndrome [20,21]. This study has shown that guide-
lines adherence and in-hospital mortality correlate signiﬁ-
cantly.
In the present study we tried to analyze the factors
inﬂuencing on the risk of death in hospital after STEMI with
respect to its modiﬁability by treatment. It is important to
know the impact of treatment-related factors to the risk of
death in order to concentrate medical care efforts on such
factors.
It is already known that the majority of factors contributing
to in-hospital mortality from MI and STEMI are associated in
particular with patient clinical status at admission and cannot
be modiﬁed by hospital treatment. These factors are age
[5,6,22–27], ST-segment deviation [5,6], AH [6,28], smoking
[6,28], family history of PHD [6], prior stroke, untreated
dyslipidaemia [6,23], diabetes [6,23], low SBP (up to hypoten-
sion, which is associated with the increasing Killip class of
AHF) [5,6], Killip class (up to cardiogenic shock) [5,22,25,29],
cardiac arrest at presentation [5], LVEF (up to congestive heart
failure) [27], elevated cardiac markers [5,6], HR [5,24,25], prior
treatment with aspirin, known CAD (stenosis 50%) and
severe angina (2 episodes within 24 h) [6].
In our study we conﬁrmed the importance of the majority of
above-mentioned patient-related factors. Some of these
factors were qualiﬁed as the main ones and the other as
additional. We have identiﬁed the following main patient-
related factors of in-hospital mortality: male sex (some studies
obtained the opposite result [30,31]), acute LV aneurism,
pathological Q-wave on ECG, blood glucose level, triglyceridelevel and RV dilatation. In-hospital mortality of STEMI patients
was not associated with the history of AH. We also showed
that DBP had more impact on in-hospital mortality risk in
patients with STEMI than SBP. As for TIMI study [6], only the
age was fully consistent with our results on major patient-
related risk factors.
Comprehensive information on impact of treatment-relat-
ed factors on in-hospital mortality in patients with STEMI was
absent in literature. We have shown that hospital treatment
with ACE-Is, ARBs, b-blockers and statins are the main
treatment-related factors of in-hospital mortality. Among
the set of all signiﬁcant predictors of in-hospital mortality
these medications were the most modiﬁable factors inﬂuenc-
ing the risk of death. The ﬁrst additional treatment-related
predictor of in-hospital mortality in our study was hospital
treatment with aspirin. It is of interest that C.P. Gale et al.
considered aspirin and out-of-hospital thrombolysis as the
strongest predictors of in-hospital survival in patients with
STEMI [24].
The key point in treatment of STEMI is reperfusion [32,33].
Prompt reperfusion for all eligible patients with STEMI is a
present-day challenge for healthcare. In context of present
research, the performance of reperfusion evaluated in terms of
ACC/AHA measures was one of treatment-related factors
inﬂuencing on the risk of death in hospital after STEMI.
Gharacholou et al. [34] have previously shown that the absence
of timely performed reperfusion is associated with greater in-
hospital mortality in patients with STEMI without contra-
indications. The results of our study in Russian patients with
STEMI suggest that reperfusion may reduce short-term
mortality risk, if it is performed additionally to basic treatment
with main drugs such as ACE-Is, ARBs, b-blockers and statins,
which are the main predictors of in-hospital mortality. In [35] it
was shown that the mortality beneﬁts from primary PCI and
the hazard of primary PCI-related delay depend on baseline
risk due to patients-related factors.
Previously, it was found out that the absolute reduction of
the risk of mortality from ﬁbrinolytic therapy or primary PCI
depend on the patient baseline risk [36]. Our results conﬁrmed
this conclusion.
For patients with STEMI treated with primary PCI, it is
known that renal insufﬁciency is an independent predictor of
in-hospital mortality [37,38]. The results of the present study
did not conﬁrm it.
Shao et al. [39] has shown that differences in therapeutic
approach inﬂuenced on thirty-day mortality from any reason
in STEMI patients. The authors have also revealed gender-
related differences in therapeutic approaches. Reperfusion
therapy was more often applied to male patients than female
ones. As the result, female patients had worse prognosis
than male patients. According to [39], the frequency of b-
blockers, ACE-Is, statins and other drugs administration in
Chinese patients with STEMI was signiﬁcantly higher in men
than in women. Similar gender differences in mortality due
to differences in treatment in patients with STEMI were
reported by some other authors [40–43]. According to their
results, reperfusion therapy gave the main impact on
mortality.
In STEMI population with small in-hospital mortality rate
(1.9%) [44], evidence-based medications (aspirin, statins,
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 2 1 7 – e 2 2 7 e225b-blockers, etc.) were prescribed to the majority of enrolled
patients during hospitalization. It was shown in [45] that
evidence-based treatments with both reperfusion (ﬁbrinolytic
reperfusion or primary PCI) and drug (aspirin, b-blockers,
statins, ACE-Is, etc.) decrease in-hospital mortality in patients
with STEMI from 12.5% to 7.2%. Similar value of evidence-
based drug administration was shown in [46,47]. The results of
our study revealed greater inﬂuence of some drugs prescrip-
tion on in-hospital mortality than early reperfusion. But it is
unquestionable that the performance of reperfusion is the
major factor inﬂuencing on long-term survival of patients with
STEMI [32,33].
It is obvious that all above mentioned risk predictors are
important for short-term prognosis of patients with STEMI and
should be taken into account during patients' hospital stay,
especially treatment-related factors. In our study we exam-
ined the peculiarities of in-hospital mortality predictors in
Russian patients with STEMI.
Study limitations
The results have been derived from selected population of
Russian ACS patients included in the Russian ACS Registry.
Thus, the results extrapolation to the ACS patients from other
countries is limited.
Various external factors (non-clinical factors, cancer,
anemia, dementia, prior non-cardiac surgery, etc.) that were
not taken into account may impact on the results of our study.
We cannot account for all such factors, especially unmeasured
characteristics.
Since the patients with STEMI who have died were older
and often had a history of prior MI, diabetes, congestive heart
failure, prior stroke and higher prevalence of AHF Killip class
>1 (Table 2), the higher mortality in patients not receiving
these drugs could partially be the result of severity of illness.
The results of the study were derived from the data on ACS
patients included in the Russian ACS Registry with voluntary
participation. Since participation in the Russian ACS Registry
was voluntary, the centers, which participated in it could be
highly equipped and highly motivated willing to expose their
practice to criticism. It is probable that these centers more
often adhere to guidelines. Thus, extrapolation of results to
ACS patients of the whole country, as well as from other
countries is limited.
We did not include subjects older than 80 years in this
study. The reasons to exclude them are indicated in the
Methods section. Exclusion of all patients over 80 years limits
the extrapolation of the results.
In the present study, the date and/or the time of several
ﬁndings and interventions were not considered (see the Data
source section). It was caused by the absence of corresponding
information in the Russian ACS Registry database. Missing
such data may inﬂuence the results of the study.
We revealed the statistically signiﬁcant differences in
administration of ACE-Is/ARBs in STEMI patients who have
died during the ﬁrst 24 h after admission and later. These
differences were not determined by the patient clinical status.
The extent of their inﬂuence on the total in-hospital mortality
needs further investigation.Conclusion
The majority of leading predictors of in-hospital death in
Russian STEMI patients was associated with the patient
clinical status at hospital presentation and can not be modiﬁed
by treatment. The treatment with ACE-Is or ARBs, b-blockers
and statins during the hospital stay (not necessarily at arrival)
inﬂuenced the risk of death in hospital as strong as the clinical
status of patient at admission. The results of our study assume
that these inpatient interventions should be carefully con-
trolled and improved to reduce in-hospital mortality from
STEMI. It is also shown that reperfusion and its quality are
additional factors, which inﬂuence indirectly on the risk of
death in hospital in Russian patients with STEMI.
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